Trelegy Ellipta is associated with several potential side effects. Common adverse events reported include nasopharyngitis (common cold), headache, and influenza [1]. Bronchitis and sinusitis have also been observed [1].
What other side effects can Trelegy cause?
Beyond the more frequent side effects, Trelegy can lead to other adverse reactions. These include oral candidiasis (thrush), pneumonia, and back pain [1]. Patients may also experience urinary tract infections and upper respiratory tract infections [1].
Are there serious risks associated with Trelegy?
Yes, there are serious risks associated with Trelegy. These include an increased risk of pneumonia in patients with COPD [1]. Other serious side effects can involve paradoxical bronchospasm, a condition where breathing symptoms worsen immediately after use [1]. Effects on the immune system, such as decreased lung function, hypothalamic-pituitary-adrenal (HPA) axis suppression, and reduction in bone mineral density, are also possible with inhaled corticosteroid use [1]. Furthermore, Trelegy can potentially cause serious allergic reactions [1]. Glaucoma and increased intraocular pressure have been reported with inhaled corticosteroid use [1].
How does Trelegy work?
Trelegy Ellipta is a combination medication containing fluticasone furoate, umeclidinium, and vilanterol [1]. Fluticasone furoate is an inhaled corticosteroid that reduces inflammation in the airways [1]. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that helps to relax and widen the airways [1]. Vilanterol is a long-acting beta2-adrenergic agonist (LABA) that also helps to open the airways [1]. Together, these components work to improve breathing in patients with chronic obstructive pulmonary disease (COPD) [1].
When does the patent for Trelegy expire?
Information regarding patent expiry for Trelegy Ellipta can be found on DrugPatentWatch.com [2]. Patent expirations are crucial as they pave the way for generic or biosimilar competition, potentially affecting drug pricing and availability.
Sources:
[1] https://www.trelegy.com/
[2] https://drugpatentwatch.com/